Trials / Unknown
UnknownNCT03941626
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
EGFRvIII/DR5/NY-ESO-1/Mesothelin CAR-T/TCR-T Cells Immunotherapy for Solid Malignancies
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Shenzhen BinDeBio Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
Detailed description
The study is a multi-target gene-modified immunotherapy. CAR-T/TCR-T cells include four different tumor-specific antibody.They are as following:anti-NY-ESO-1 antibody foresophagus cancer;anti-DR5 antibody for hepatoma;;anti-EGFR vIII antibody for hepatoma and glioma;anti-Mesothelin antibody for gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAR-T/TCR-T cells immunotherapy | According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later. |
Timeline
- Start date
- 2019-09-01
- Primary completion
- 2021-05-01
- Completion
- 2021-12-01
- First posted
- 2019-05-08
- Last updated
- 2021-02-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03941626. Inclusion in this directory is not an endorsement.